Dark Forest Capital Management LP Purchases Shares of 38,148 Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Dark Forest Capital Management LP acquired a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 38,148 shares of the biopharmaceutical company's stock, valued at approximately $359,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Summit Investment Advisors Inc. boosted its stake in shares of Amicus Therapeutics by 4.4% during the 4th quarter. Summit Investment Advisors Inc. now owns 30,696 shares of the biopharmaceutical company's stock worth $289,000 after purchasing an additional 1,280 shares during the period. Xponance Inc. boosted its position in shares of Amicus Therapeutics by 11.9% during the fourth quarter. Xponance Inc. now owns 21,216 shares of the biopharmaceutical company's stock valued at $200,000 after buying an additional 2,249 shares during the period. Covestor Ltd grew its stake in shares of Amicus Therapeutics by 114.9% during the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock valued at $41,000 after buying an additional 2,312 shares during the last quarter. KBC Group NV raised its holdings in shares of Amicus Therapeutics by 44.4% in the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock worth $96,000 after buying an additional 3,120 shares during the period. Finally, Swiss National Bank lifted its stake in shares of Amicus Therapeutics by 0.7% during the 4th quarter. Swiss National Bank now owns 437,500 shares of the biopharmaceutical company's stock worth $4,121,000 after acquiring an additional 3,200 shares during the last quarter.

Wall Street Analyst Weigh In

A number of analysts have weighed in on FOLD shares. StockNews.com lowered Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, February 20th. The Goldman Sachs Group reduced their price target on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research note on Friday. UBS Group boosted their price objective on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Friday. Wells Fargo & Company dropped their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research note on Thursday, February 20th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Amicus Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $16.22.

Amicus Therapeutics Stock Down 0.1 %

FOLD stock traded down $0.01 during trading on Friday, hitting $6.67. 6,371,892 shares of the company's stock traded hands, compared to its average volume of 2,692,364. The firm has a market capitalization of $2.05 billion, a P/E ratio of -37.06, a PEG ratio of 1.51 and a beta of 0.79. Amicus Therapeutics, Inc. has a 1 year low of $6.20 and a 1 year high of $12.65. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. The business has a fifty day simple moving average of $7.95 and a two-hundred day simple moving average of $9.29.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.